Clostridium difficile in the Pediatric Population of Monroe County, New York

Susan M Rhee1, Rebecca Tsay2, Deborah S Nelson2

  • 1Divison of Infectious Diseases, Johns Hopkins Bayview Medical Center, Baltimore, Maryland.

Insights

Pediatric Clostridium difficile infection (CDI) is rising, with most cases occurring in the community. Children with CDI often have underlying conditions and prior antibiotic use, highlighting the need for judicious antibiotic stewardship.

Area of Science:

  • Pediatric Infectious Diseases
  • Epidemiology
  • Public Health Surveillance

Background:

  • Clostridium difficile infection (CDI) incidence in hospitalized children has increased.
  • CDI cases are increasingly reported in the community setting.
  • Accurate burden estimation requires surveillance of both hospitalized and non-hospitalized pediatric cases.

Purpose of the Study:

  • To describe the epidemiology of pediatric Clostridium difficile infection in Monroe County, New York.
  • To understand the trends and characteristics of CDI in children.
  • To inform public health strategies for CDI prevention.

Main Methods:

  • Active, laboratory, and population-based surveillance for CDI.
  • Surveillance conducted in Monroe County, NY, through the CDC's Emerging Infections Program since 2010.
  • Exclusion of infants under 12 months of age.

Main Results:

  • Pediatric CDI incidence was 33.8 per 100,000 in 2010, rising to 45.8 in 2011, then stabilizing.
  • 71% of cases were community-associated.
  • 60% had underlying medical conditions, and 71% had prior antibiotic exposure. The NAP1 strain was found in 27% of cases.

Conclusions:

  • CDI is an emerging pediatric disease in both community and hospital settings.
  • Community-acquired CDI is more prevalent in this pediatric population.
  • Judicious antibiotic use, particularly outpatient, is crucial for prevention. Further studies are needed to identify preventable risk factors.
Abstract

Related Concept Videos

Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
55
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
32
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704